Newport Laboratories will toll manufacture and distribute Merial autogenous porcine circovirus type 2 swine vaccines through Newport’s veterinarian and swine integrator customer base. The Merial vaccines complement Newport Laboratories’ CircoSpan line of solution-based diagnostics, technical support, strain specific production and customer focused consultation.   
 
“We see this relationship as a perfect match for the swine business units of each company,” said Steve Parker, director of swine marketing, Merial U.S. Region. “Merial will contribute product technical support through a working relationship with Newport. Newport will contribute its sales and marketing capability, including strong relationships with top swine veterinarians, swine producers and key influence leaders.
 
“The relationship leverages both companies’ strengths,” says Randy Simonson, Newport chief operating officer. “The use of Merial products and technology, along with the support of our strong sales and technical field force will enhance the profitability of U.S. pork producers through solution-based animal health care offerings.”
 
Combined with the existing Newport and Merial collaboration on SwiVax-MH and Derma-Vac NF Transdermal needle-free vaccination system, this new relationship optimizes Merial’s product technology with Newport’s demand realization capabilities, providing a unique opportunity to meet the needs of U.S. swine producers.
 
Merial is an innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial is a joint venture between Merck and sanofi-aventis. Newport Laboratories is headquartered in Worthington, Minn. Newport Laboratories was established to assist food animal veterinarians in finding antigen-based solutions to animal health problems through diagnostic testing and production of autogenous biologics.